Calcium polystyrene sulfonate
Brand names: Calcium Resonium
Calcium polystyrene sulfonate is an oral or rectal cation-exchange resin used to treat or prevent hyperkalaemia, including in chronic kidney disease where potassium excretion is impaired.
Adult dose
Paediatric dose
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
⚠ THIS IS A DAILY TOTAL, NOT A PER-DOSE FIGURE — hence unit 'g/kg/day'. Divide the calculated daily total across the day's doses. VERBATIM §4.2 (Paediatric population, oral): 'In smaller children and infants correspondingly smaller doses should be employed by using as a guide a rate of 1mEq of potassium per gram of resin as the basis for calculation. An appropriate initial dose is 1g/kg body weight daily in divided doses, in acute hyperkalaemia. Dosage may be reduced to 0.5g/kg body weight daily in divided doses for maintenance therapy.' So: ACUTE 1 g/kg/day (the value stored above), MAINTENANCE 0.5 g/kg/day, both in divided doses. 🔴 NEONATES: 'Calcium Resonium should not be given by the oral route' — this is also a §4.3 contraindication in neonates with reduced gut motility (post-operative or drug-induced). For neonates, only the rectal route is described, and 'the minimum effective dosage within the range 0.5g/kg to 1g/kg should be employed, diluted as for adults with adequate irrigation to ensure recovery of the resin.' In children and neonates particular care is needed with rectal administration, as excessive dosage or inadequate dilution could result in impaction of the resin; faecal impaction following rectal administration has been reported particularly in children. concentration is null because the product is a powder for oral/rectal suspension with no fixed mg/ml strength — it is reconstituted at 3 to 4 ml per gram of resin at the point of use, so no concentration figure exists in this label. Verify any under-18 dose against a children's formulary and local guidance before prescribing.
Contraindications
- Plasma potassium levels below 5 mmol/litre
- Conditions associated with hypercalcaemia (e.g. hyperparathyroidism, multiple myeloma, sarcoidosis or metastatic carcinoma)
- History of hypersensitivity to polystyrene sulfonate resins
- Obstructive bowel disease
- Must not be given orally to neonates, and is contraindicated in neonates with reduced gut motility (post-operative or drug-induced)
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
Side effects
- Hypokalaemia and hypercalcaemia and their related clinical manifestations — the resin's own pharmacological actions; hypomagnesaemia has also been reported
- Hypercalcaemia reported in well dialysed patients receiving calcium resin and occasionally in patients with chronic renal failure; some patients who cannot be screened out beforehand show a sudden rise in serum calcium to high levels after therapy
- Gastrointestinal: gastric irritation, anorexia, nausea, vomiting, constipation and occasionally diarrhoea
- Faecal impaction following rectal administration (particularly in children) and gastrointestinal concretions (bezoars) following oral administration
- Gastrointestinal stenosis and intestinal obstruction — possibly due to co-existing pathology or inadequate dilution of the resin
- Gastrointestinal ischaemia, ischaemic colitis, gastrointestinal tract ulceration or necrosis which could lead to intestinal perforation — sometimes fatal
- Acute bronchitis and/or broncho-pneumonia associated with inhalation of particles of calcium polystyrene sulfonate
Monitoring
- Serum potassium — the dosage is a guide only and precise requirements should be decided on the basis of regular serum electrolyte determinations; STOP the resin when the serum potassium falls to 5 mmol/litre. Adequate clinical and biochemical control is essential, especially in patients on digitalis, because of the possibility of severe potassium depletion
- Serum calcium — 'Serum calcium levels should be estimated at weekly intervals to detect the early development of hypercalcaemia, and the dose of resin adjusted to levels at which hypercalcaemia and hypokalaemia are prevented' (§4.4)
- All applicable electrolytes — the resin is not totally selective for potassium; hypomagnesaemia and/or hypercalcaemia may occur, so patients should be monitored for all applicable electrolyte disturbances
- Bowel function and abdominal symptoms — seek prompt review for severe abdominal pain, nausea and vomiting, stomach distension or rectal bleeding; discontinue for clinically significant constipation until normal bowel movement resumes
Clinical monograph
How it works
In the gut the resin exchanges calcium ions for potassium ions, which are then bound to the resin and eliminated in the faeces, lowering total body potassium.
Prescribing in practice
- Avoid in obstruction or reduced gut motility and do not give with sorbitol, as the combination has been associated with intestinal necrosis; it is not appropriate for life-threatening hyperkalaemia, which needs emergency treatment.
- It releases calcium and so can cause hypercalcaemia; the calcium form is often preferred over the sodium form where sodium load must be limited.
- Onset is slow over hours, so it is for ongoing potassium control rather than acute emergencies; separate from other oral medicines to avoid binding them.
Monitoring
Monitor serum potassium and calcium during treatment, stopping or reducing therapy once potassium normalises to avoid hypokalaemia.
Counselling the patient
- This medicine lowers potassium gradually and is not a treatment for sudden severe high potassium.
- Report constipation, severe abdominal pain or vomiting promptly.
- Take it separated from your other tablets to keep them working.
Evidence & guidelines
MHRA advice warns against co-administration of polystyrene sulfonate resins with sorbitol owing to the risk of gastrointestinal injury, and these resins remain established options for chronic hyperkalaemia.
Reference: UK Renal Association; MHRA Drug Safety Update; NICE TA599; NICE TA623; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Hyperkalaemia Management Algorithm · Electrolyte Disorders
- PLASMIC Score for TTP · Haematological Diagnosis
- Sickle Cell Exchange Transfusion Volume · Transfusion Medicine
- Hour-Specific Bilirubin Risk Assessment (Bhutani Nomogram) · Neonatal Jaundice
- Neonatal Partial Exchange Transfusion for Polycythaemia · Neonatal Haematology
- Erasmus GBS Outcome Score (EGOS) · Guillain-Barre Syndrome
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019